{"doi":"10.1002/mds.28641","title":"Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3 Years in Patients with Early Parkinson's Disease","abstract":"BACKGROUND: The Quality of Life in Neurological Disorders (Neuro-QoL) is a publicly available health-related quality-of-life measurement system. OBJECTIVE: The aim of this study was to evaluate the utility of Neuro-QoL item banks as outcome measures for clinical trials in Parkinson's disease. METHODS: An analysis of Neuro-QoL responsiveness to change and construct validity was performed in a multicenter clinical trial cohort. RESULTS: Among 310 participants over 3 years, changes in five of eight Neuro-QoL domains were significant (P < 0.05) but very modest. The largest effect sizes were seen in the cognition and mobility domains (0.35-0.39). The largest effect size for change over the year in which levodopa was initiated was -0.19 for lower extremity function-mobility. For a similarly designed clinical trial, estimated sample size required to demonstrate a 50% reduction in worsening ranged from 420 to more than 1000 participants per group. CONCLUSIONS: More sensitive tools will be required to serve as an outcome measure in early Parkinson's disease. © 2021 International Parkinson and Movement Disorder Society.","journal":"Movement Disorders","year":2021,"id":196769,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.8944,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":341993,"name":"Kelly A. Mills","orcid":"0000-0002-4302-1501","position":1,"is_corresponding":false},{"id":80295,"name":"Shirley Eberly","orcid":"0009-0005-2338-2499","position":2,"is_corresponding":false},{"id":341995,"name":"David Oakes","orcid":"0000-0002-9154-6054","position":3,"is_corresponding":false},{"id":376246,"name":"Kelvin L. Chou","orcid":"0000-0002-2597-7315","position":4,"is_corresponding":false},{"id":341994,"name":"Matthew Halverson","orcid":"0009-0003-4224-1400","position":5,"is_corresponding":false},{"id":199007,"name":"Sotirios A. Parashos","orcid":null,"position":6,"is_corresponding":false},{"id":317518,"name":"Christopher G. Tarolli","orcid":"0000-0003-0422-4020","position":7,"is_corresponding":false},{"id":381534,"name":"Jin‐Shei Lai","orcid":"0000-0003-1840-2537","position":8,"is_corresponding":false},{"id":769973,"name":"Cindy J. Nowinsky","orcid":null,"position":9,"is_corresponding":false},{"id":769518,"name":"Oksana Suchowersky","orcid":"0000-0001-6783-4956","position":10,"is_corresponding":false},{"id":769974,"name":"Eric S. Farbman","orcid":null,"position":11,"is_corresponding":false},{"id":539246,"name":"Lisa M. Shulman","orcid":"0000-0002-1652-1201","position":12,"is_corresponding":false},{"id":246441,"name":"Tanya Simuni","orcid":"0000-0002-2347-1644","position":13,"is_corresponding":false},{"id":341997,"name":"Connie Marras","orcid":"0000-0002-9236-9328","position":0,"is_corresponding":true}],"reference_count":20,"raw_metadata":null,"created_at":"2026-07-18T23:50:15.704473Z","pmid":"33983638","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}